Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab. Puzzolo MC, Radice G, Peragine N, de Propris MS, et al. Blood 2021 Jul 23. pii: 476452. doi: 10.1182/blood.2021011822.

Read + Share

Amedeo Smart

Independent Medical Education

Puzzolo MC, Radice G, Peragine N, de Propris MS, et al. Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab. Blood 2021 Jul 23. pii: 476452. doi: 10.1182/blood.2021011822.
PMID: 34297829